Search clinical trials for: GSK233705 25mcg

Total 318 results

GlaxoSmithKline

Completed

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Romania, Bulgaria, Argentina, Canada, Chile, Philippines, South Africa, Thailand, Netherlands, Korea, Republic of, Hungary, United Kingdom
GlaxoSmithKline

Completed

A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD (DB2113361)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Ukraine, Estonia, Belgium, France, Sweden, Netherlands, Philippines, Denmark, Hungary, Norway, Slovakia
GlaxoSmithKline

Completed

Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Belgium, Sweden
GlaxoSmithKline

Completed

A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

28-day Repeat Dose Study of GSK573719

Pulmonary Disease, Chronic Obstructive

United States, Estonia, Germany, Poland
GlaxoSmithKline

Completed

Phase I Study of GSK233705 in Healthy Japanese Male Subjects

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects

Hepatitis C

United States
GlaxoSmithKline

Completed

Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805

Hepatitis C

United States
GlaxoSmithKline

Completed

A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.

Pulmonary Disease, Chronic Obstructive

Netherlands
The University of Queensland
Syneos Health; Coalition for Epidemic Preparedness Innovations

Completed

A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

Covid19 | SARS-CoV2

Australia
GlaxoSmithKline

Completed

A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD (DB2113373)

Pulmonary Disease, Chronic Obstructive

Japan, Russian Federation, Spain, United States, Bulgaria, Canada, Poland, South Africa, Thailand, Mexico, Chile, Greece, Czechia
Faes Farma, S.A.

Completed

Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency (WORFEROL)

Vitamin D Deficiency | Vitamin D Insufficiency

Spain, France, Bulgaria, Czechia, Italy, Serbia, Slovakia
Janssen R&D Ireland

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

Healthy

United States
GlaxoSmithKline

Completed

A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.

Hepatitis C

United States
GlaxoSmithKline

Completed

A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function

Asthma

New Zealand
GlaxoSmithKline

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Estonia, Canada, Chile, Germany, Peru, Philippines, Mexico, Korea, Republic of, Denmark, Russian Federation, Poland, Slovakia
Sihuan Pharmaceutical Holdings Group Ltd.

Unknown

Janagliflozin Treat T2DM Monotherapy

Diabetes Type 2

China
Can-Fite BioPharma

Not yet recruiting

Namodenoson Treatment of Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Adenocarcinoma

Israel
Idorsia Pharmaceuticals Ltd.
Janssen Biotech, Inc.

Completed

A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects

Healthy Subjects

United States
University of Dundee

Completed

Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics (MAN05)

Asthma

United Kingdom
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of SYHA1402 in Healthy Subjects

Diabetic Peripheral Neuropathy
AstraZeneca

Completed

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

Solid Tumors

United States
Percheron Therapeutics

Active, not recruiting

A Study of ATL1102 or Placebo in Participants With Non-ambulatory Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United Kingdom, Australia, Serbia, Turkey, Bulgaria
Haisco Pharmaceutical Group Co., Ltd.

Completed

Relative Bioavailability and Pharmacodynamics of HSK7653 in Healthy Volunteers

Healthy

China
GlaxoSmithKline
PPD

Completed

Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C, Chronic

Puerto Rico, United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People

Diabetic Neuropathy Peripheral

China
University of Oxford
European and Developing Countries Clinical Trials Partnership (EDCTP); Institut...

Completed

Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso

Malaria,Falciparum

Burkina Faso
GlaxoSmithKline

Completed

Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers

Irritable Bowel Syndrome (IBS) | Irritable Colon

United States
DBV Technologies

Completed

Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy (PEPITES)

Peanut Allergy

United States, Canada, Germany, Australia, Ireland
Ascletis Pharmaceuticals Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

Acne Vulgaris

China
Federico II University

Completed

Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ Damage

Hypertension | Ventricular Remodeling | Erectile Dysfunctions

Italy
GlaxoSmithKline

Completed

A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Impairment.

Pulmonary Disease, Chronic Obstructive

Czechia
GlaxoSmithKline

Completed

A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.

Asthma

Czechia, Slovakia
GlaxoSmithKline

Completed

A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline
PPD

Completed

Dose Ranging of GSK2336805 in Combination Therapy (HAI115879)

Hepatitis C, Chronic

Puerto Rico, United States, Bulgaria, Germany, Belgium, France
Shire

Completed

Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism (PARALLAX)

Hypoparathyroidism

United States, Hungary, Canada, Denmark
Targacept Inc.

Completed

Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
GlaxoSmithKline

Completed

Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

Hepatitis C

United States
LG Chem

Completed

An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)

Type 2 Diabetes Mellitus

China
GlaxoSmithKline

Completed

Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany
Baylor Research Institute

Not yet recruiting

Outcomes of Once-Daily ICS/LABA/LAMA Plus PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations (Sundial-COPD)

Copd

United States
TWi Biotechnology, Inc.

Completed

Study of AC-201 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Taiwan
Cephalon
H. Lundbeck A/S; The Parkinson Study Group

Terminated

Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease

Parkinson Disease

United States, Canada, Puerto Rico
GlaxoSmithKline

Completed

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, Poland, Romania, United States, Czechia, Russian Federation
Chong Kun Dang Pharmaceutical

Unknown

Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin

Diabetes Mellitus, Type II

Korea, Republic of

3

Subscribe